Literature DB >> 20724066

Does reduced [(123)I]-FP-CIT binding in Huntington's disease suggest pre-synaptic dopaminergic involvement?

Josep Gamez1, Carles Lorenzo-Bosquet, Gemma Cuberas-Borrós, Francesc Carmona, Jorge Hernández-Vara, Joaquin Castilló, Joan Castell-Conesa.   

Abstract

OBJECTIVE: To evaluate the usefulness of SPECT in assessing damage to the pre-synaptic dopaminergic system in Huntington's disease (HD) using [(123)I]-FP-CIT (DaTSCAN), a selective radioligand with regulatory approval as the diagnostic test for investigating functional dopaminergic neuron loss in the striatum in Parkinson's disease.
METHODS: We studied twelve symptomatic HD patients using DaTSCAN/SPECT imaging. [(123)I]-FP-CIT caudate and putamen uptake levels were qualitatively and semi-quantitatively analyzed to assess pre-synaptic damage in the striatal dopamine system. Possible correlations were analyzed between HD severity on the Unified Huntington's Disease Rating Scale (UHDRS), duration of clinical symptoms, and [(123)I]-FP-CIT/SPECT striatal uptake.
RESULTS: DaTSCAN/SPECT qualitative analysis showed reduced striatal uptake in eight patients. Semi-quantitative analysis revealed a significant reduction in four. Of these four, uptake reduction was at putamen level in all, and also at caudate level in one. Although we observed no linear correlation between HD severity and reduced striatal [(123)I]-FP-CIT uptake, the patients with the worst UHDRS scores had more severe reductions in radioligand uptake.
CONCLUSION: This is the first study to use in vivo [(123)I]-FP-CIT/SPECT imaging to confirm prior descriptions using PET of a pre-synaptic dopaminergic system defect in HD.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20724066     DOI: 10.1016/j.clineuro.2010.07.014

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  8 in total

1.  Is the time ripe to adopt semiquantitative analysis of SPECT evaluation in movement disorders as a standard?

Authors:  Federico Caobelli; Barbara Paghera; Raffaele Giubbini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

2.  Reversible abnormal functional neuroimaging presentations in polycythemia vera with chorea.

Authors:  Hui-Chun Huang; Yu-Chin Wu; Lee-Yung Shih; Woei-Chung Lo; Chon-Haw Tsai; Woei-Cherng Shyu
Journal:  J Neurol       Date:  2011-05-11       Impact factor: 4.849

3.  Dual phase 18F-FP CIT PET and 99mTc- ECD SPECT findings of Huntington's disease.

Authors:  KyungAh Chun
Journal:  Radiol Case Rep       Date:  2022-05-09

4.  Atypical Parkinsonism Revealing a Late Onset, Rigid and Akinetic Form of Huntington's Disease.

Authors:  A Ciammola; J Sassone; B Poletti; N Mencacci; R Benti; V Silani
Journal:  Case Rep Neurol Med       Date:  2011-09-07

Review 5.  Neuropsychiatric Burden in Huntington's Disease.

Authors:  Ricardo Augusto Paoli; Andrea Botturi; Andrea Ciammola; Vincenzo Silani; Cecilia Prunas; Claudio Lucchiari; Elisa Zugno; Elisabetta Caletti
Journal:  Brain Sci       Date:  2017-06-16

Review 6.  Functional neuroimaging and chorea: a systematic review.

Authors:  Debra J Ehrlich; Ruth H Walker
Journal:  J Clin Mov Disord       Date:  2017-06-21

7.  99mTc-TRODAT-1 SPECT Revealed That Striatal Dopamine Transport Availability Significantly Decreases in Late Mid-Aged Healthy Taiwanese and Then Remains Stable.

Authors:  Skye Hsin-Hsien Yeh; Chi-Jung Tsai; Tsung-Hsun Yu; Yung-Hsiao Chiang; Shinn-Zong Lin; Nan-Jing Peng; Wen-Sheng Huang
Journal:  Clin Nucl Med       Date:  2022-03-01       Impact factor: 7.794

8.  Anti-CV2/CRMP5 Paraneoplastic Chorea Effectively Managed with Intravenous Amantadine.

Authors:  Jongmok Ha; Boo Suk Na; Jong Hyeon Ahn; Minkyeong Kim; Jae Woo Kim; Jae Hyeok Lee; Jin Whan Cho; Ji Sun Kim; Jinyoung Youn
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2019-10-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.